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Summary
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The lactate dehydrogenase-A (LDH-A) enzyme catalyzes the inter-conversion of pyruvate and
lactate, is upregulated in human cancers and is associated with aggressive tumor outcomes. Here
we use a novel inducible murine model and demonstrate that inactivation of LDH-A in mouse
models of NSCLC driven by oncogenic K-RAS or EGFR leads to decreased tumorigenesis and
disease regression in established tumors. We also show that abrogation of LDH-A results in
reprogramming of pyruvate metabolism, with decreased lactic fermentation in vitro, in vivo, and
ex vivo. This was accompanied by re-activation of mitochondrial function in vitro but not in vivo
or ex vivo. Finally, using a specific small molecule LDH-A inhibitor, we demonstrated that LDH-A
is essential for cancer initiating cell survival and proliferation. Thus, LDH-A can be a viable
therapeutic target for NSCLC including cancer stem cell-dependent drug resistant tumors.

Introduction

NIH-PA Author Manuscript

The enhancement of aerobic glycolysis i.e. the Warburg effect (lactate production in the
presence of adequate oxygen) (Warburg, 1930, 1956) not only provides cancer cells with a
survival advantage, but also links it to invasive ability (Gatenby and Gillies, 2004). This
effect has been seen in different types of tumors and the concomitant increase in glucose
uptake is exploited clinically for detection of tumors by 2-fluorodeoxyglucose-based
positron emission tomography (FDG-PET) (Gillies, 2001; Hsu and Sabatini, 2008).
Non-small cell lung cancer (NSCLC) is highly glycolytic, accounts for >85% of all lung
cancers (Gazdar and Minna, 1999) and is the leading cause of cancer deaths. Mutations at
codon 12, which constitute the majority of K-RAS mutations (Forbes et al., 2006) promote
fermentative glycolysis in NSCLC (Vizan et al., 2005). Enhanced fermentative glycolysis in
a hypoxic tumor microenvironment results in increased acid production (Ebert et al., 1996),
which in turn lowers extracellular pH and has been linked to the metastatic ability of cancer
cells (Fischer et al., 2007; Walenta et al., 1997).

NIH-PA Author Manuscript

K-RAS mutations have been frequently reported in NSCLC, particularly in adenocarcinoma
(Riely et al., 2009). Mutations in EGFR are also common in NSC adenocarcinomas, and are
generally exclusive with K-RAS mutations. Somatic activating mutations in EGFR produce a
constitutively active tyrosine-kinase (L858R) and tumors bearing these mutations respond to
the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (Amann et al., 2005;
Kobayashi et al., 2005). Clinically, despite the dramatic responses to such inhibitors, most
patients relapse, owing to acquiring the resistance mutations (T790M, and L747S) (Costa et
al., 2007). Any potential therapeutic opportunity that can address highly glycolytic NSCLC
will have a significant clinical impact.
Tumor initiating cells (TICs) or cancer stem cells (CSCs) comprise a small population of
tumor-forming, self-renewing, cancer cells within a tumor and are associated with
aggressive disease and poor prognosis (Ailles and Weissman, 2007). It has been suggested
that CSCs cluster in hypoxic niches, rely on fermentative glycolysis and have decreased
mitochondrial respiration similar to progenitor cells during normal development (Hill et al.,
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2009; Zhou et al.). Glycolysis is known to be indispensable for progenitor proliferation and
biosynthesis (Agathocleous et al., 2012).
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Targeting tumor metabolism via anti-glycolytic therapies may offer a therapeutic
opportunity as it represents a key converging step for multiple deregulated signaling
pathways in cancer cells. The lactate dehydrogenase-A gene (LDH-A), a target for HIF-1α
and MYC, is of particular interest because it catalyzes the NADH-dependent reduction of
pyruvate to lactate, a step essential for regenerating the NAD+, which is needed for
maintaining glycolysis and other metabolic activities. Enhanced expression of LDH-A has
been associated with evolution of aggressive and metastatic cancers in a variety of tumor
types (Koukourakis et al., 2005). Since therapies to address highly glycolytic NSCLC
tumors are limited, development of LDH-A inhibitors may have a significant impact on this
patient population.
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Here, we detail the generation of a tamoxifen regulated cre-recombinase conditional mouse
model of LDH-A deletion (Cretm-LDH-Afl/fl). To investigate the role of LDH-A in NSCLC,
we have used Ccsp-rtTA/(tetO)7-K-RAS4bG12D bitransgenic mice (Fisher et al., 2001) and
Ccsp-rtTA/(tetO)-EGFR L858R-T790M (Regales et al., 2007) to generate Cretm-LDHAfl/fl;Ccsp-rtTA/(tetO)7-K-RAS4bG12D and Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)-EGFRL858R-T790M respectively. These Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)7-K-RAS4bG12D and
Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)-EGFR-L858R-T790M mice serve as preclinical models
in which tumors can be initiated in lung tissue by induction of mutant K-RAS or EGFRL858R-T790M by doxycycline while LDH-A can be removed in all adult tissues including
the lung. This model has enabled us to test the impact of LDH-A inhibition in established
tumors. We show that LDH-A expression is required for the development of K-RAS
dependent tumors. Importantly, we also show that blockade of LDH-A is therapeutically
efficacious in established mutated K-RAS and EGFR-L858R-T790M dependent tumors.
Indeed, established tumors regress with reduced LDH-A.
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We have also examined the impact of LDH-A suppression on cancer metabolism in vitro.
We have previously shown that LDH-A abrogation leads to increased production of reactive
oxygen species (ROS) and apoptosis in cancer cells, likely the result of increased respiration
(Xie et al., 2009). Here, using stable isotope tracers coupled with metabolomic analysis
(stable isotope-resolved metabolomics or SIRM), we demonstrated that LDH-A suppression
in cultured cancer cells enhances the Krebs cycle, oxygen consumption and mitochondrial
ROS production (Seth et al., 2011). Moreover, using SIRM, we have investigated the
metabolic effect of LDH-A attenuation in vivo in our new mouse model and ex vivo in
freshly prepared human NSCLC tissue slices. Similar to the in vitro result, glycolytic
production of 13C-lactate from 13C6-glucose was attenuated in LDH-A suppressed mouse
lung tumors and LDH-A inhibitor-treated human tumor slices, but the Krebs cycle activity
was not activated either in vivo or ex vivo.
It has been speculated that cancer stem cells exhibit the Warburg phenotype and may benefit
from anti-glycolytic therapies. We demonstrate that oncogenic K-RAS–expressing cancer
stem cells are highly susceptible to loss of LDH-A expression. We also validate these
findings using an LDH-A specific inhibitor.
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Generation and characterization of Cretm-LDH-Afl/fl mice
Since LDH-A deletion is embryonic lethal (data not shown), we have generated conditional
LDH-A transgenic mice controlled by tamoxifen-regulated cre-recombinase (Cretm) for
inducible inactivation the LDH-A gene. The schematic (Figures S1 A–H) describes LDH-A
gene inactivation.
Loss of LDH-A results in hemolytic anemia
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Within 6 weeks of tamoxifen treatment, Cretm-LDH-Afl/fl mice but not LDH-Afl/fl developed
severe but non lethal hemolytic anemia as evidenced by reduced numbers of red blood cells
(RBCs) in the peripheral blood (Figure S2A). Blood smears stained with May-GrunwaldGiemsa marked polychromasia indicating release of early RBCs from the marrow in
response to peripheral hemolysis (Figure S2C). The spleens of transgenic animals were
greatly enlarged due to marked expansion of red pulp from hyperplastic erythroid
precursors, and increased hemosiderin deposits characteristic of RBC phagocytosis were
evident (Figures S2B, C). Flow cytometry analysis further confirmed the expansion of
CD71+Ter119+ immature erythroblasts in the bone marrow, spleen and peripheral blood of
Cretm-LDH-Afl/fl animals (Figure S2D). Notably, tamoxifen-treated Cretm-LDH-Afl/+
animals developed a partial phenotype (Figures S2A–D), as evident in both morphologic and
flow-cytometric analyses, demonstrating that LDH-A is haplo-insufficient with respect to
erythropoiesis.
Reduction in LDH-A protein levels results in decreased tumorigenesis in a K-RAS driven
NSCLC model
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In order to generate mice that have all the alleles, Cretm-LDH-Afl/fl mice were mated with
Ccsp-rtTA/(tetO)7-K-RAS4bG12D (hereafter referred to as K-RAS) to generate Cretm-LDHAfl/fl;Ccsp-rtTA/(tetO)7-K-RAS4bG12D (homozygous for LDH-A, hereafter referred as
Cretm-LDH-Afl/fl; K-RAS) or Cretm-LDH-Afl/+;Ccsp-rtTA/(tetO)7-K-RAS4bG12D
(heterozygous for LDH-A, hereafter referred to as Cretm-LDH-Afl/+;K-RAS). In these mice,
addition of doxycycline turns on the oncogenic K-RAS expression in a lung specific manner
and intraperitoneal injection of tamoxifen turns off LDH-A expression in all the adult
organs. Similarly, control LDH-Afl/fl-Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice lacking the
Cretm gene were generated (hereafter referred to as LDH-Afl/fl;K-RAS).
To assess the role of LDH-A in the initiation of oncogenic K-RAS tumors, we took 5 week
old Cretm-LDH-Afl/fl;K-RAS and Cretm-LDH-Afl/+;K-RAS mice and initiated doxycycline
treatment for an additional two weeks to activate mutant K-RAS (Figure 1A). Following that,
we initiated intraperitoneal tamoxifen injection (10 mg ml−1) in corn oil every day for 5
days. We validated success of cre-recombination by RT-PCR analysis by assessing loss of
exon 2 and sequencing the truncated LDH-A protein (Figures S1I–K). The control was the
identical experiment where we injected corn oil as a vehicle with the same schedule.
As shown in Figure 1, reduced LDH-A expression resulted in significant reduction in tumor
area, suggesting that fermentative glycolysis is a key bioenergetic pathway in oncogenic K-

Cell Metab. Author manuscript; available in PMC 2015 May 06.

Xie et al.

Page 5

NIH-PA Author Manuscript

RAS driven tumors. The data also show that deletion of just one allele of LDH-A results in
substantial tumor reduction in this model (Figures 1B, C). The decreased expression of
LDH-A in lung tumors was verified by western blot analysis. No changes were detected in
LDH-B expression when LDH-A gene was deleted (Figures 1D, E). To validate the effects of
LDH-A abrogation in vivo, a single Cretm-LDH-Afl/fl;K-RAS mouse was imaged using proton
MRI (Figure 1F) and hyperpolarized 13C MRSI (Figures 3F–H) before and after inactivation
of LDH-A by tamoxifen administration. As shown (Figures 1F–H), the solid lesions
exhibited reductions in the lactate-to-pyruvate ratio levels in the tumor just 10 days after
final tamoxifen treatment. For the larger lesion, the ratio fell from 0.47±0.01 to 0.37±0.05,
while for the smaller lesion the ratio fell from 0.50±0.04 to 0.31±0.10. The spectra
illustrating this reduction in the smaller lesion are shown (Figure 1H). Furthermore,
abrogation of LDH-A in tumors led to decreased lactate levels, an increased NAD+/NADH
ratio, and increased pyruvate and isocitrate levels (Figure 1I), all consistent with decreased
mitochondrial oxidation.

NIH-PA Author Manuscript

Cleaved caspase-3 immunohistochemical analysis (IHC) showed increased apoptosis in KRAS driven tumors that have reduced LDH-A expression (Figure 1J). We also observed
reduced disease in lungs of tamoxifen-treated Cretm-LDH-Afl/fl;K-RAS mice using high
resolution axial CT images of lung/chest (Figure 1K).
Reduction in LDH-A protein levels results in regression of established tumors in a K-RAS
driven NSCLC model
To assess whether inhibition of LDH-A in an established tumor can impact tumor
progression, five week old Cretm-LDH-Afl/fl;K-RAS and Cretm-LDH-Afl/+;K-RAS mice were
maintained on a doxycycline diet for an additional 9 weeks. Following that, we initiated
intraperitoneal tamoxifen injections (10 mg ml−1) in corn oil every day for 5 days (Figure
2A).
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Deletion of just one allele of LDH-A results in substantial tumor reduction in this GEM
model (Figures 2B, C). The decreased expression of LDH-A in lung tumors was verified by
western blot analysis and no changes were detected in LDH-B expression when LDH-A gene
was deleted (Figure 2D). The degree of LDH-A attenuation is consistent with the
homozygous and heterozygous knockdown. Furthermore, to quantify the response of LDH-A
ablation on tumor growth in Cretm-LDH-Afl/fl;K-RAS in real time, we scanned Cretm-LDHAfl/fl;K-RAS and LDH-Afl/fl;K-RAS mice pre and the post-tamoxifen treatment. We observed
marked regression in tumor growth 10 day post last tamoxifen treatment as measured by
coronal and transverse section CT imaging (Figures 2F, G) and representative volumetric
assessment of the total lung volume (Movie S1). These results suggest that targeting LDH-A
in a K-RAS driven tumor results in tumor regression and targeting LDH-A in lung cancer
might have therapeutic efficacy.
Reduction in LDH-A protein levels results in decreased tumorigenesis and regression of
established tumors in EGFR resistant NSCLC model
It is possible that other aggressive lung tumors such as those that are resistant to EGFR
inhibitors would be amenable to therapeutic targeting via LDH-A. To test this hypothesis, we
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generated a Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)-EGFR-L858R-T790M mouse model
(referred as Cretm-LDH-Afl/fl;EGFR-T790M). These mice express EGFR mutation L858R as
well as T790M mutation. Similar to the K-RAS model, the EGFR-L858R-T790M expression
can be activated in lung epithelial cells by doxycycline and LDH-A expression (whole body)
can be modulated by administering tamoxifen.

NIH-PA Author Manuscript

Five week old Cretm-LDH-Afl/fl;EGFR-T790M, Cretm-LDH-Afl/+;EGFR-T790M and LDHAfl/fl;EGFR-T790M mice were maintained on a doxycycline diet for additional 8 weeks, as
shown (Figure 3A). The response of LDH-A suppression on tumor growth in Cretm-LDHAfl/+;EGFR-T790M was quantified in real time, we performed MRI scans of Cretm-LDHAfl/fl;EGFR-T790, Cretm-LDH-Afl/+;EGFR-T790 and LDH-Afl/fl;EGFR-T790 mice pre and
post tamoxifen treatment. We show marked regression in tumor growth 20 days post after
the last tamoxifen treatment as measured by coronal and transverse section imaging by CT
scan (Figures 3B, C) and volumetric assessment of total lung volume. The graphical
representation of volumetric analysis is shown as net change in lung volume (Figure 3E).
The decreased expression of LDH-A in lung tumors was verified by western blot analysis
(Figure 3D). The data also show that deletion of LDH-A results in substantial tumor
reduction similar to the K-RAS model. These results suggest that targeting LDH-A in
EGFRT-790M driven tumors results in tumor regression. However, unlike the K-RAS
tumors where heterozygous ablation of LDH-A was therapeutically efficacious, the EGFRT790M driven tumors showed a smaller decrease and 1 out of 4 tumors showed increase in
tumor growth in the 4th week of monitoring.
Genetic and pharmacologic targeting of LDH-A suppress cancer stem cell function
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We next asked whether CSCs are susceptible to reduction in LDH-A levels. To investigate
the in vivo role of LDH-A in tumor initiating capacity in oncogenic K-RAS tumors, we
isolated tumor cells from Cretm-LDH-Afl/fl;K-RAS or Cretm-LDH-Afl/fl;K-RAS mice that
were treated with tamoxifen. As shown in Figure 4, when introduced via tail vein in
C57BL6 mice, tumor cells with diminished LDH-A expression colonized the lung at a
significantly decreased rate compared to tumor cells that have normal levels of LDH-A
expression (Figure 4B). Injection of A549 cells expressing control or LDH-A shRNA in tail
vein metastasis assay in athymic mice gave similar results (Figure 4A). Reduction in LDH-A
expression in both A549 and Cretm-LDH-Afl/fl;K-RAS was confirmed by western
immunoblotting (Figures 4C, D). These findings are consistent with an in vitro matrigel
invasion assay with NSCLC A549 cells expressing LDH-A shRNA (Figure 4C). Collectively
these data suggest that blockade of fermentative glycolysis diminishes tumor initiating
capacity, possibly via blocking cancer stem cells.
Next, to assess the role of LDH-A on CSCs in vitro, we next down-regulated LDH-A by
shRNA in A549 cells and seeded them in a tumorsphere formation assay. As shown (Figures
4E, F), down-regulation of LDH-A expression significantly reduced the ability of A549 cells
to form tumorspheres. To assess whether these results can be recapitulated in another
oncogenic RAS cell line, we utilized a well-established RAS -induced mammary
tumorigenesis system (HMLER) that has been used for CSCs analysis (Al-Hajj et al., 2003;
Mani et al., 2008). We found that down regulation of LDH-A in this system results in a
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significant decrease in CSCs as assessed by tumorsphere assay and by the expression of
CD24/44 markers (Figure 4G). We further showed that tumor cells isolated from lungs of
tamoxifen-treated Cretm-LDH-Afl/fl;K-RAS mice formed significantly fewer tumorspheres
than lung cells from LDH-Afl/fl;K-RAS mice, suggesting that LDH-A abrogation impacts
cancer stem cells in vivo (Figures 4H, I).
To validate these findings with LDH-A suppression, we used a specific inhibitor of LDH-A
(Compound 1) developed at GlaxoSmithKline (Figure 5A). Compound 1 inhibited
recombinant human LDH-A enzyme with an Ki = 4.8 ± 1.1 nM and showed ~10-fold
selectivity over LDH-B (Figure 5B) and results in apoptosis (Billiard et al., 2013).
Compound 1 decreased cellular lactate production in HepG2 hepatocellular carcinoma cells
with an EC50 = 588 ± 200 nM (Figure 5C), increased ROS production (Figure 5D),
decreased extracellular acidification rate (Figure 5E), and increased oxygen consumption
rate (Figure 5F).
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We also found that down regulation of LDH-A activity by Compound 1 reduced the ability
of A549 cells to form tumorspheres (Figures 5G, H) and decreased the number of CD24/44
positive cells in HMLER system (Figure 5I) and in stem cells isolated from HMLER (Figure
S5A). To investigate whether the observed decrease in CSCs is specific, we cultured
HMLER cells with 10 μM Compound 1 for 48 hours before re-plating them in presence or
absence of Compound 1. Figure 5J shows that CD24/44 positive cells re-appear after
withdrawal of the inhibitor suggesting that Compound 1 affects CSC phenotype. Finally,
treatment with Compound 1 significantly reduced the number of tumorspheres generated by
tumor cells isolated from lungs of Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice (Figures 5K, L).
To investigate the specificity of LDH-A inhibitor targeting stem v/s. non-stem, we
performed proliferation assay, which showed that the LDH-A inhibitor does not exclusively
target stem cells, but the impact on stem cells is significant compared to non-stem cells (S.
Figure 5B). To extend our results, we also used another previously published stem cell
system i.e. MCF10A cells expressing shPTEN or over-expressing PIK3CA (Hanai et al.,
2013) to demonstrate that an LDH-A inhibitor reduced the stem cell population as assessed
by the tumorsphere assay (Figure 6C).
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Abrogation of LDH-A results in reactivation of mitochondrial function in cancer cells in
vitro
In order to test the hypothesis that reduction in aerobic glycolysis as a result of LDH-A
abrogation leads to reactivation of mitochondrial metabolism, we performed 13C6-glucose
(Glu) and 13C5,15N2-glutamine (Gln) tracer experiments with A549 cells expressing control
shRNA or LDH-A shRNA. We found by GC-MS increased amounts of total and 13Cenriched Krebs cycle metabolites (citrate, cis-aconitate, αKG, fumarate, malate, and
aspartate) derived from either [U-13C] glucose (Figure 6A) or [U-13C]-glutamine, (Figure
6B). In particular, the increased synthesis of doubly 13C labeled (13C2- or m2-) and
quadruply 13C labeled (13C4- or m4-) citrate from 13C6-glucose in LDH-A suppressed cells
reflect enhanced Krebs cycle activity through the first and second turns, respectively (cf.
atom-resolved pathway tracing in Figure 6A). Increased flux through the Krebs cycle in
these cells was also evidenced by the enhanced accumulation of the 13C4-isotopologues of
Cell Metab. Author manuscript; available in PMC 2015 May 06.
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citrate, fumarate and malate derived from fully labeled glutamine during the first turn of the
cycle (cf. Figure 6B). In contrast, 13C enrichment of Glu was substantially attenuated
(e.g. 13C515N-Glu or m6-Glu in Figure 6B) by LDH-A suppression in A549 cells grown
with 13C5,15N2-Gln. The GC-MS result was corroborated by the 1D HSQC NMR data, as
shown (Figure S6), where the abundance of the 13C-3/13C-4-Glu and 13C-4-Glu-glutathione
isotopomers was lower in LDH-A suppressed than in control cells. Even more attenuated
was the abundance of 13C-4-Gln, which could be accounted for by decreased uptake and/or
increased utilization of labeled Gln through the Krebs cycle; the latter is consistent with
increased synthesis of labeled products of 13C5,15N2-Gln oxidation through the Krebs cycle
(cf. Figure 6B). We further noted that despite the reduction in levels of all 13C labeled Glu
isotopologues in LDH-A suppressed cells (Figure 6B), their fractional enrichment in these
cells was comparable to that in control cells (Figure S6). The lack of change in 13C
fractional distribution together with decreased abundance of Glu and Gln is consistent with
both reduced uptake of glutamine and increased glutaminolysis via the Krebs cycle induced
by LDH-A knockdown. Enhanced pyruvate carboxylation observed could represent another
anaplerotic path enhanced in LDH-A suppressed cells perhaps to compensate for the
decreased Gln uptake. Overall decreased synthesis of glutathiones (reduced and oxidized
forms) and increased mitochondrial metabolism is expected to lead to increased levels of
ROS.
The above findings are in line with our hypothesis that ROS generated in response to LDH-A
inhibition as a result of increased flux of pyruvate into the mitochondria. We have also
demonstrated that these ROS are indeed mitochondrial in origin (data not shown). The static
metabolic profiles from Cretm-LDH-Afl/fl;K-RAS or Cretm-LDH-Afl/+;K-RAS tumors (Figure
1I, H and Figure S3) corroborated the 13C tracer analysis of increased Krebs cycle activity
as well as reduced glutathione synthesis and increased NAD+/NADH ratio in LDH-A
suppressed cells.
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Our mouse model provides a unique opportunity to investigate metabolic reprogramming in
tumors in vivo in live animals via SIRM, using 13C6 glucose as tracer in the Cretm-LDHAfl/fl;K-RAS and LDH-Afl/fl;K-RAS mice post tamoxifen treatment. Figure 7A shows 13C
abundance data of lactate and other key metabolites in lung tumors derived from labeled
glucose for 4 separate experiments. Relative to the control lung tumors (LDH-Afl/fl;K-RAS),
LDH-A suppressed lung tumor (Cretm-LDH-Afl/fl;K-RAS) had reduced synthesis of 13Clactate (cf. 13C-3-Lac) (p<0.03) which is consistent with reduced LDH-A activity. LDH-A
knockdown lung tumors also led to reduced 13C incorporation from labeled glucose into the
Krebs cycle metabolites, including Asp, Glu, Gln, succinate, and citrate, although these
effects did not reach statistical significance by Wilcoxon analysis (Figure 7, & Figure S4A).
Nonetheless, this in vivo result contrasts with the enhanced Krebs cycle activity induced by
LDH-A knockdown in cell culture (Figure 6). Metabolic distinctions between in vivo and in
vitro systems have been observed for other tumors (Marin-Valencia et al., 2012), which
could result from tumor micro-environmental factors absent in cell culture systems,
including interaction with stromal cells and variable nutrient supply and oxygenation. Figure
7B shows the corresponding 1H NMR spectra for one of the tumor pairs in Figure 7A.
Unlabeled lactate (cf. H-3-Lac) and Ala (H-3-Ala) did not change while 13C-Lac and Ala
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(cf. 13Csat-3 peaks) depleted with LDH-A knockdown. This result is consistent with reduced
glycolytic flux from glucose to lactate, while lactate production from non-glucose sources
may not have changed in response to LDH-A suppression.
To test how human lung tumor tissue metabolism responded to LDH-A attenuation, we
employed ex vivo cancerous lung tissues freshly resected and thinly sliced from a human
NSCLC patient (akin to “Warburg” slices). Similar tissue slices from other patients maintain
metabolic activity (e.g. lactate and ATP synthesis) for up to 24 h under our culture
conditions (data not shown). When tissue slices each were incubated with LDH-A inhibitor
(Compound 1) + 13C6-glucose or with inhibitor + 13C5,15N2-glutamine for 24 h, 13C-lactate
production from labeled glucose (Figure 7C) was reduced while that from labeled glutamine
was not (Figure 7D), which indicates a block in the LDH-A activity by the inhibitor without
altering glutamine metabolism to lactate, corroborating with the LDH-A knockdown mouse
tumor result described above (cf. Figure 7B). However, we noted reduced 13C incorporation
from labeled glutamine into the Krebs cycle metabolites such as succinate, citrate, and Asp
(cf. Figure 7D) in response to LDH-A inhibition, which is consistent with the data obtained
from LDH-A knockdown mice but deviates from the in vitro cell culture result (cf. Figure 6).
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Discussion
This study allows us to reach a number of important conclusions: 1) reduced LDH-A
expression in the adult mouse results in non-lethal anemia, but no other obvious toxicities;
2) reduced LDH-A expression in highly glycolytic tumors that expresses oncogenic K-RAS
and/or EGFR L858R mutation in addition to resistant mutation T790M results in decreased
tumorigenesis and regression of established tumors and as such may provide therapeutic
benefit; 3) both homozygous and heterozygous deletion of LDH-A provides therapeutic
efficacy; 4) LDH-A attenuation leads to reduced glycolytic flux in vivo, ex vivo, and in vitro
but reactivation of the TCA cycle and anaplerosis occurs only in vitro, implicating the
important role of the microenvironment in tumor metabolic reprogramming; 5) LDH-A
inhibition impacts CSCs, a population of cells not targeted by most current therapies.
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We show that loss of a single allele of LDH-A also results in decreased tumorigenesis.
Therefore, it is likely that partial inhibition by a small molecule inhibitor directed against
LDH-A may have potential anti-tumor activity. Of interest, we did not see compensation by
increased expression of LDH-B, though we cannot rule out that the activity of this enzyme
was not increased. These effects of LDH-A ablation on oncogenic K-RAS driven tumor
growth were shared by tumors carrying EGFR L858R and T790M mutations, which render
them insensitive to EGFR inhibitors.
Our data also show that LDH-A plays a critical role in tumor progression. Previous work
from others and us has shown that that LDH-A suppressed cancer cell lines exhibit reduced
tumor progression in xenograft models (Fan et al., 2011a; Fantin et al., 2006; Wang et al.,
2011). These studies represent an important milestone in validating LDH-A as a therapeutic
target, but they suffer from well-known artifacts of utilizing xenografts (Frese and Tuveson,
2007). Here we circumvented these issues by using a genetically engineered mouse (GEM)
model. In this model, we temporally ablated LDH-A expression, enabling the investigation
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of LDH-A’s role in tumor regression as well as in by-stander effect on non-tumor cells,
which better approximates the use of a LDH-A inhibitor in a clinical setting. LDH-A ablation
led to regression of an established tumor without serious systemic toxicity.
To our knowledge, this report is the first to show that abrogation of a metabolic enzyme in
an established tumor model results in reduction of the tumor burden. In fact, metabolically
targeted therapies generally delay tumor progression (Patra et al., 2013) or are cytostatic
without causing regression (Bonnet et al., 2007; Hatzivassiliou et al., 2005).
In recent years, we have come to appreciate how substrate utilization is dictated by
oncogenic enzymes (Nilsson et al., 2012). Based on our work, it is reasonable to hypothesize
that all RAS transformed tumors and tumors with EFGR L858R mutations including those
develop resistance to EGFR inhibitor therapy may respond to LDH-A inhibition.
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By using labeled tracers and SIRM analysis, we were able to define metabolic
reprogramming in lung tumor cells following LDH-A abrogation, i.e. increased flow of
carbon from both glucose and glutamine through the Krebs cycle but reduced synthesis of
glutathiones from glutamine. These reprogrammed events presumably underlie the enhanced
oxygen consumption rate (OCR) and increased generation of ROS, previously observed by
us (Xie et al., 2009). However, the mitochondrial perturbations in cultured tumor cells
induced by LDH-A ablation was not recapitulated in vivo in our mouse model or ex vivo in
human lung tumor slices, except for the reduced synthesis of glutathione’s. Such
discrepancies between in vivo and in vitro results have been observed in other tumor systems
(e.g. glioma) (Marin-Valencia et al., 2012), and highlight the importance of tumor
microenvironment and possibly systemic influence on tumor metabolic reprogramming,
which in turns underlies inhibition of tumor growth or development.
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Several publications described novel inhibitors of LDH-A, but most of the inhibitors are
either inactive in cell based assays (Dragovich et al., 2013; Kohlmann et al., 2013) or have
other problems (Le et al., 2010) as detailed in (Ward et al., 2012). The inhibitor used here
(Billiard et al., 2013) is active in cell based assays at low μM concentrations in number of
cell lines (Figure 5, and data not shown) and phenocopies the CSC results generated with
either a cell line expressing LDH-A shRNA or tumors isolated from Cretm-LDH-Afl/fl;K-RAS
animals. Our attempts to use the LDH-A inhibitor for in vivo work, either in xenografts or
GEMs, were limited by its pharmacokinetic properties.
Although it has been speculated that CSCs reside in hypoxic niche (Lock et al., 2013; Zhang
et al., 2012) but relatively little is known about the metabolic properties of these cells. We
show that reduced LDH-A expression impacts CSCs using established in vivo, in vitro, and
ex vivo assays. Some of these findings were further validated with our novel LDH-A specific
inhibitor. As in the case for non CSCs, these effects are likely to be mediated via
perturbations to the mitochondrial Krebs cycle, as CSCs produce more ROS compared to
non-stem counterpart. The ROS production by CSCs was further enhanced by LDH-A
suppression (Figures S7A, B). Thus, CSCs could be more vulnerable to LDH-A blockade
due to the overall lower capacity of their Krebs cycle (with limitation at the succinate
dehydrogenase or SDH step of Complex II), despite a low glycolytic capacity, relative to the
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non-CSCs (cf. Figure S7C). Complex II is prone to producing superoxide, and its over
burden in LDH-A suppressed CSCs may account for the observed excess production of
ROS. The Krebs cycle together with the electron transport chain would be less able to
oxidize the excess pyruvate or regenerate NAD+ in the cytoplasm via the malate/Asp shuttle
to sustain glycolysis. The finding that LDH-A inhibition/ablation impacts cancer stem cells,
a population of cells not targeted by a vast majority of current therapies, sets the stage for
pre-clinical combinatorial trials with currently approved therapies for NSCLC.

Experimental Procedures
Cells and cell culture
A549 and HepG2 cells were purchased from the American Type Culture Collection and
maintained in Ham’s F-12 medium (Mediatech, Inc) with 10% FCS and penicillin/
streptomycin (P/S). Immortalized human breast epithelial cells (HMLE), were gifts from Dr.
Weinberg (Whitehead Institute). All cell lines were grown as described earlier (Hanai et al.,
2013).
Flow cytometry analysis and Fluorescence-Activated Cell Sorting (FACS)
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HMLER cells were FACS-sorted into stem cell population (S: CD44 high and CD24 low)
and non stem cell population (NS: CD44 low and CD24 high) as described earlier (Hanai et
al., 2013).
Tumorsphere formation assay
Single cells were plated in 6-well ultra-low attachment plates (Corning) at a density of
~20,000 viable cells/ml and were processed as described earlier (Hanai et al., 2013). Two
tailed t test was used to evaluate the statistical significance of the results. All values are
expressed as mean ± S.E for this assay.
Oxygen consumption and PPR analysis by XF24 seahorse platform
The XF24 Extracellular Flux analyzer (Seahorse Biosciences, Billerica, MA) was used to
measure oxygen consumption (OCR) and extracellular acidification rate (ECAR). Results
were expressed as % ECAR or % OCR.
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Steady State Metabolic analysis
Metabolic analysis was performed by BIDMC mass spectrometry core facility. Sample
preparation was done according to a procedure developed by the core. Data were analyzed
by the web server software located at http://www.metaboanalyst.ca/MetaboAnalyst/faces/
Home.jsp. The normalized data were plotted using PRISM software.
Tamoxifen Treatment
All animal studies and procedures were approved by BIDMC Institutional Animal Care and
Use Committee and were conducted in accordance with the BIDMC policy on the Care,
Welfare and Treatment of Laboratory Animals. As described in the results section, the mice
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were treated with tamoxifen (10 mg ml−1 in corn oil) or corn oil (only for fig. 3B) (Sigma)
by intraperitoneal injection. A total of 76 mice were used in all the experiments.
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Doxycycline Treatment
Doxycycline chow (Harlan, Teklad) was used as described previously (Fisher et al., 2001).
PCR genotype and western blot analysis
PCR primers developed by SANGER were used to detect modified LDH-A allele. Western
blot analysis was carried out to further validate loss of LDH-A protein.
Statistical Analysis
Means, medians, Welch two tailed t-tests, Wilcoxon rank-sum test and descriptive-statistics
were calculated as appropriate using Prism software package or Kaleidagraph (Synergy
Software). The Error bars represented in each figure are mean +/− SD or +/− SEM and
appropriate analysis is indicated in figure legends. P value p< 0.05 was considered
statistically significant.
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Tumor initiating cell assay
Athymic mice were injected via tail vein with either A549 cells (104 in 100μl) that were
either expressing control shRNA or LDH-A shRNA. For tumor initiating cell assay in
syngenic mice, tumor cells (104 in 100μl) isolated from either corn oil or tamoxifen treated
Cretm-LDH-Afl/fl;Ccsp-rtTA/(tetO)7-K-RAS4bG12D mice were injected via tail vein. Animals
were monitored for 21 days post injection and euthanized as per established guidelines.
Total number of animals used for these assays were 20.
Tumor area measuring and Lung metastasis assay
Lung organs from 2mice bearing RAS-driven tumor were removed and washed three times
with PBS. Formalin-fixed, paraffin-embedded mouse lung tissue sections were prepared at 5
μm. Each slide 2 or 3 sections cut from different distance were collected and stained by
H&E method. H&E stained slides were scanned and tumor area were quantified with Image
J (NIH software).

NIH-PA Author Manuscript

LDH enzymatic and Lactate production assay
These assays were performed as described earlier (Billiard et al., 2013).
Hyperpolarizer and proton imaging
All imaging procedures were approved by our Institutional Animal Care and Use Committee
(IACUC) using methods described previously (Seth et al., 2011). 13C magnetic resonance
spectroscopic imaging (MRSI) was performed using two-dimensional chemical shift
imaging (2D CSI) as described (Kohler et al., 2007).
Micro CT studies
Animals were anesthetized with 2% isoflurane/balance O2. Imaging was performed using
the CT component of a NanoPET/CT (Bioscan, Washington, DC) scanner and image
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analysis was performed using VivoQuant software (inviCRO, Boston, MA) using a
Hounsfield Unit windowing technique, normalized for all scans. Volumetric segmentation
was performed using a neighborhood threshold.
SIRM analysis
SIRM studies with 13C-enriched tracers were carried out as previously described for both
cells in culture and in mice (Fan et al., 2011b; Fan et al., 2012). Metabolites were analyzed
by GC-MS and NMR according to standardized protocols as previously described (Lane et
al., 2008), using in-house databases of standards for identification (Fan and Lane, 2008).
Isotopomer distributions and fractional enrichments were calculated as previously described
(Lane et al., 2008).
Warburg Slices
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“Warburg slices” are thin slices (<1 mm thick) of tissue, two of which were immediately cut
from a freshly resected human NSCLC tumor using a Weck microtome and were maintained
in DMEM medium supplemented with 10% FBS, 1X penicillin and streptomycin plus
0.2% 13C6-glucose and 2 mM glutamine or 0.2% glucose and 2 mM 13C5,15N2-glutamine
under 5% CO2 at 37°C for 24 h without or with 20 μM Compound 1. The tissues were
harvested by rinsing briefly in cold PBS, blotted dry and weighed before flash frozen in
liquid N2. Metabolites were extracted and analyzed by 1H{13C} HSQC NMR as described
previously (Fan et al., 2011b; Fan et al., 2012).

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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•

An inducible LDH-A mouse model has been developed and characterized.

•

Reduced LDH-A results in regression of established tumors in NSCLC mouse
models.

•

Cancer initiating cells are susceptible to LDH-A inhibition.

•

Pharmacologic inhibition of LDH-A mimics the effects of genetic attenuation.
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Fig. 1. LDH-A expression is required for initiation of oncogenic K-RAS-induced tumorigenesis
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(A) Schematic representation of an experiment where LDH-A knockdown was initiated 14
days after K-RAS induction by doxycycline diet. (B) Tumor areas of Cretm-LDH-Afl/fl;KRAS mice treated with tamoxifen (n=7) or corn oil (n=6). (C) Tumor areas of Cretm-LDHAfl/fl;K-RAS (n=3), Cretm-LDH-Afl/+;K-RAS (n=5) and LDH-Afl/fl;K-RAS (Cretm negative)
mice (n=4) treated with tamoxifen (data in B and C are represented as mean ± SD, *= p <
0.05, **= p <0.01 as calculated by two tailed t test). (D) Representative western blot
analysis of tumor (along with non-malignant cells) for LDH-A, LDH-B, and beta-actin from
LDH-Afl/fl;K-RAS and Cretm-LDH-Afl/fl;K-RAS mice. (E) Representative western blot
analysis of tumor (along with non-malignant cells) for LDH-A, and beta-actin from LDHAfl/fl;K-RAS and Cretm-LDH-Afl/+;K-RAS mice (F) Coronal proton density weight images
showing comparison of lungs in Cretm-LDH-Afl/fl;K-RAS mouse on doxycycline diet (left)
and Cretm-LDH-Afl/fl mouse (right). Tumors are indicated by arrows in image on left. (G)
Proton (left), pyruvate (center), and lactate (right) images acquired in Cretm-LDH-Afl/fl;KRAS mice prior to tamoxifen administration. Red outlines are drawn around lung lesions.
(H) Spectra acquired before (two left panels) and after (two right panels) tamoxifen
withdrawal, with signals from pyruvate (pyr) and lactate (lac) labeled at left. (I) Metabolic
profiling analysis of NADH, NAD+, isocitrate, lactate, and pyruvate from LDH-Afl/fl;K-RAS
v/s. Cretm-LDH-Afl/fl;K-RAS (see Fig. S3 for other pathway specific metabolites). (J)
Representative caspase-3 staining of tumors from Cretm-LDH-Afl/fl;K-RAS (top panel), and
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LDH-Afl/fl;K-RAS (bottom panel); quantitation of caspase 3 staining is shown on the right
(means ± SD of n= 4 mice each). (K) Axial CT images and anterior/posterior (A/P)
reconstruction from chest/lung and H&E staining of a lung section from LDH-Afl/fl;K-RAS
(left panel) and Cretm-LDH-Afl/fl;K-RAS treated with tamoxifen (right panel).
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Fig. 2. Reduction in LDH-A levels results in reduced tumorigenesis of established tumors in a KRAS-driven NSCLC model

(A) Schematic representation of an experiment where LDH-A knockdown was initiated ~83
days after K-RAS induction by doxycycline diet. (B & C) Tumor areas of Cretm-LDHAfl/fl;K-RAS (n=12), Cretm-LDH-Afl/+;K-RAS (n=7), and LDH-Afl/fl;K-RAS (n=6) mice that
were treated with tamoxifen. Data is representated as mean ± SD, **=p, 0.01, *= p < 0.05
(two tailed t test) (D) Representative western blot analysis of tumors (along with nonmalignant cells) from LDH-Afl/fl;K-RAS, Cretm-LDH-Afl/+;K-RAS, and Cretm-LDH-Afl/fl;KRAS mice for LDH-A, LDH-B, and beta-actin. (E) Axial CT images and anterior/posterior
(A/P) reconstruction from chest/lung from LDH-Afl/fl;K-RAS mice (left panel) and CretmLDH-Afl/fl;K-RAS mice treated with tamoxifen (right panel) with tumors indicated by arrows
(F) Representative coronal and transverse images of lung/chest from same pre and post
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tamoxifen treated Cretm-LDH-Afl/fl;K-RAS mice (n=5) in comparison to LDH-Afl/fl;K-RAS
mice (n=3).
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Fig. 3. Reduction in LDH-A levels results in reduced tumorigenesis of established tumors in
EGFR- L858R-T970M driven NSCLC model

NIH-PA Author Manuscript

(A) Schematic representation of an experiment where LDH-A knockdown was initiated ~80
days after EGFR-T970M mutation induction by doxycycline diet. (B & C) Representative
axial CT scans from pre and post Tamoxifen tumor volume of Cretm-LDH-Afl/fl;EGFRT970M, Cretm-LDH-Afl/+;EGFR-T970M mice. (D) Representative western blot analysis of
tumors (along with non-malignant cells) from LDH-Afl/fl;K-RAS, Cretm-LDH-Afl/+;K-RAS,
and Cretm-LDH-Afl/fl;K-RAS mice for LDH-A, and beta-actin. (E) Graphical representation
of volumetric changes in lung volume pre and post tamoxifen Cretm-LDH-Afl/fl;EGFRT970M (n=5), Cretm-LDH-Afl/+; EGFRT-970M (n=4), and LDH-Afl/fl; EGFRT970M (n=4)
mice that were treated with tamoxifen. Statistical data values are significant as tested by
Dunnett’s multiple comparisons test between all three genotypes (* WT to heterozygous and
*** WT to homozygous).
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Fig. 4. LDH-A knockdown results in reduction of oncogenic K-RAS-induced cancer stem cells

NIH-PA Author Manuscript

Top Panel: Cancer-initiating cells within oncogenic K-RAS-expressing tumors are
susceptible to LDH-A abrogration. (A) Cancer-initiating lesions from lungs of syngeneic
mice (n=5) that were injected via tail vein with A549 cells expressing either control shRNA
or LDH-A shRNA. Cancer-initiating lesions in (A) and (B) were scored after 24 days. (B)
Cancer-initiating lesions from lungs of syngeneic mice (n=5) that were injected via tail vein
with isolated tumor cells from tamoxifen-treated Cretm-LDH-Afl/fl;K-RAS (n=3) or LDHAfl/fl;K-RAS (n=2) mice. Data is expressed as ± SEM (**=p < 0.01). (C) In vitro matrigel
invasion assay with A549 cells expressing either control shRNA or LDH-A shRNA.
Absorbance at 595 nm reflects the number of migrated cells. (D) Western immunoblotting
for LDH-A and beta-actin of cells used in in vitro invasion and in vivo cancer initiation
assays.
Bottom Panel: Stem cell populations within oncogenic ras-expressing cell lines are reduced
by LDH-A shRNA. (E) A549 human NSCLC cells expressing control shRNA or two
different LDH-A shRNAs were analyzed in tumorsphere formation assay and (F)
Quantification of the results expressed as mean ± SD (*=p < 0.05) (G) FACS analysis of
stem cell populations using CD44 and CD24 antibodies in Ras-transformed HMLE
(HMLER) and shRNA-LDH-A-HMLER. (H) Tumorsphere formation assay using tumor
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cells isolated from Cretm-LDH-Afl/fl;K-RAS or LDH-Afl/fl;K-RAS mice and (I) Graphical
quantification of the results expressed as mean ± SD (*=p <0.05).
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Fig. 5. Small molecule LDH-A inhibitor reduces the number of Ras-induced tumor stem cells
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Left Panel: (A) Chemical structure of the Compound 1. (B) Compound 1 inhibits activity of
recombinant human LDH-A (IC50=4.8±1.1 nM) and LDH-B (IC50=53.1±0.9 nM) enzymes.
The signal obtained in absence of LDH was set as 100% inhibition and the signal obtained
in absence of Compound 1 was set as 0% inhibition (DMSO control, not included on the
graphs). Data are means ± SD of two readings, representative of 6 independent experiments.
(C) Compound 1 inhibits lactate production in HepG2 human hepatocellular carcinoma
cells. Lactate concentration was normalized to cell viability assessed by CellTiter-Fluor™
assay (CTF), and the lactate/CTF ratio obtained in DMSO-treated cells was set at 100%. (D)
Compound 1 (10 μM) increases ROS activity in A549 cells as measured by DCF
fluorescence (representative of two independent experiments). (E) Compound 1 (10 μM)
increases oxygen consumption rate (OCR) and (F) decreased extracellular acidification rate
(ECAR) in A549 cells. XF-24 seahorse cell analyzer was used to obtain the data (means ±
SD of n=2).
Right Panel: (G & H) Tumorsphere formation assay with A549 cells using vehicle control
or 10 μM Compound 1 with graphical quantitation of the results expressed as mean ± SD
(*=p< 0.05). (I) FACS analysis using CD44 and CD24 antibodies for stem cell population in
ras-transformed HMLE (HMLER) treated with 0, 5 and 10 μM Compound 1 for 30 hours.
(J) Decrease in the stem cell population in HMLER by compound1 treatment is specific as
shows that CD24/44 positive cells re-appear after withdrawal of the inhibitor (a) plated in
absence of compound 1, (b) switched to media containing compound 1 for 24 hours, and (c),
switched back to media without compound 1 for additional 24 hours. (K & L) Tumorsphere
formation assay with tumor cells isolated from LDH-Afl/fl;K-RAS mice treated with DMSO
or 5 μM Compound 1, with graphical quantitation of results expressed as mean +/SD (p <
0.05).
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Fig. 6. Enhanced utilization of labeled glucose and glutamine via the Krebs cycle in LDH-A
suppressed A549 cells
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(A & B) A549 cells transduced with an empty vector (PLKO) or shRNA targeting LDH-A
(LDH) were grown in 13C6-glucose (A) or 13C5,15N2-Gln (B) tracers for 24 h, as described
in Methods. The polar extracts were analyzed by GC-MS for the distribution of various 13C
isotopologues (same metabolites with different numbers of 13C atoms) of the Krebs cycle
metabolites. Also shown in panels A and B are the atom-resolved Krebs cycle tracings with
each respective tracer. The m2 (13C2) or m4 (13C4) isotopologues derived from either tracer
via the Krebs cycle without input from pyruvate carboxylation (PC) are denoted with red
rectangles while the m3 (13C3) isotopologues derived from 13C6-glucose via PC are
highlighted with green rectangles. Metabolite concentrations are means ± SD of two or three
replicates. Solid and dashed arrows: single and multiple step reactions; single- and doubleheaded arrows: irreversible and reversible reactions, respectively; αKG: αketoglutarate;
●: 12C; , : 13C in the first and second turn without PC input; : 13C with PC input.
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Fig. 7. LDH-A suppression in Cretm-LDH-Afl/fl;K-RAS, mouse lung tumors and its
pharmacological inhibition in primary human lung tumor tissue blocked glucose oxidation via
glycolysis without activating the Krebs cycle
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(Top panel) Four each LDH-Afl/fl;K-RAS (Ctl) and Cretm-LDH-Afl/fl;K-RAS (LDH-A KO)
mice were tail vein injected with 20 mg of 13C6-glucose in sterile PBS 3 times at 15 minute
intervals prior to dissection for lung tumor tissues (one of the LDH-A KO mice had
insufficient tissue for metabolite analysis). Polar metabolites were extracted from frozen
pulverized tissue powder and analyzed by 1D 1H and 1H-{13C} HSQC NMR as described
for Warburg slices in Methods. (A) Displays the HSQC spectra for one pair of control
versus LDH-A knockdown mouse tumors, where the intensity of each assigned
metabolite 1H signal reflect the 13C abundance of the attached carbon. Also shown is the
average content (mean±SE) of selected 13C-labeled glycolytic and Krebs cycle metabolites
(as 13C μmole/g protein) obtained from the HSQC data (4 each for Ctl and LDH-A
KO). 13C-metabolites were quantified from the peak areas of respective HSQC resonances
using the 13C-3-Lac resonance as a calibrator. The 13C abundance of 3-Lac was obtained
from the 1H NMR spectra as in (B) calibrated against the DSS standard. Lac: lactate; NMePCholine: N-methyl protons of phosphocholine; Glc: glucose; G6P: glucose-6-phosphate;
UDP-GlcNAc: UDP-N-acetylglucosamine; UXP: uracil nucleotides; AXP: adenine
nucleotides. LDH-A KO induced reduced production of 13C-lactate from 13C6-glucose,
which is consistent with decreased glycolytic flow while it also elicited attenuated synthesis
of 13C-Ala, -Glu, -succinate, -citrate, and –Asp but this attenuation did not reach statistical
significance (cf. Fig. S4). Suffice to say, Krebs cycle activity was not activated by LDH-A
suppression. (B) Shows the 1H spectrum of one of the five pairs of tumors. 13Csat-3-Lac:
the 13C satellite peaks of the H3 of lactate, the pattern of which indicate fully 13C labeled
lactate; GSH+GSSG: reduced and oxidized glutathiones. Reduced production of 13C-lactate
and -Ala with little changes in the levels of the unlabeled counterparts is evident.
(Bottom panel) Two tissue slices were procured from one resected human NSCLC tumor,
each treated with 13C6-glucose and 13C5,15N2-glutamine, and processed as described in
Materials and Methods. (C and D) display respectively the 1D 1H-{13C} HSQC spectra
of 13C6-glucose and 13C5,15N2-glutamine treated slices with or without LDH-A inhibitor (10
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μM Compound 1). Also shown is the content of selected 13C-labeled glycolytic and Krebs
cycle metabolites (as 13C μmole/g protein, determined as in (A)) obtained from the HSQC
data. LDH-A inhibitor-induced reduction in 13C-lactate production from 13C6-glucose is
evident in (C) while decreased synthesis of Krebs cycle metabolites (succinate, citrate, and
Asp) and glutathiones from 13C5,15N2-glutamine in response to LDH-A inhibition is shown
in (D). Also clear from (D) is the lack of change in 13C-lactate production from 13C5,15N2glutamine with LDH-A inhibition.
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